Actively Recruiting
AZA Combined With RCHOP in P53-mutated DLBCL.
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-02-19
52
Participants Needed
1
Research Sites
131 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital of Xiamen University
Lead Sponsor
J
Jiangsu Provincial People's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma
CONDITIONS
Official Title
AZA Combined With RCHOP in P53-mutated DLBCL.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 70 years
- New diagnosis of TP53-mutated Diffuse Large B-cell Lymphoma
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Left ventricular ejection fraction (LVEF) greater than 45%
- If hepatitis B virus (HBV) positive, HBV-DNA test must be negative before enrollment
- Liver function with serum bilirubin ≤ 2.0 times upper limit of normal (ULN), serum ALT and AST ≤ 2.5 times ULN
- Renal function with serum creatinine ≤ 2.0 times ULN unless due to lymphoma
- Life expectancy of at least 6 months
- Ability to provide informed consent
You will not qualify if you...
- Primary or secondary central nervous system involvement by DLBCL
- HIV-positive status or active hepatitis C virus infection
- Clinically significant secondary cardiovascular disease
- Severe chronic obstructive pulmonary disease with combined hypoxemia
- Active bacterial, fungal, or viral infections not controlled by systemic therapy
- Other malignant tumors diagnosed within the last 3 years except cured basal cell carcinoma of the skin, cervical cancer in situ, early prostate cancer not requiring systemic therapy, or early breast cancer treated only with surgery
- Known hypersensitivity or allergic reaction to antibodies or proteins of murine origin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bing Xu
Xiamen, Fujian, China, 361000
Actively Recruiting
Research Team
B
Bing Xu
CONTACT
Z
Zhifeng Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here